Xinyang Du

552 total citations
12 papers, 329 citations indexed

About

Xinyang Du is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Xinyang Du has authored 12 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 2 papers in Molecular Biology. Recurrent topics in Xinyang Du's work include Lung Cancer Treatments and Mutations (7 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Colorectal Cancer Treatments and Studies (2 papers). Xinyang Du is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Colorectal Cancer Treatments and Studies (2 papers). Xinyang Du collaborates with scholars based in China, United States and United Kingdom. Xinyang Du's co-authors include Yanfang Liu, Hong Ma, Ye Wang, Jing Yao, Zhijie Wang, Jie Wang, Hua Bai, Jianchun Duan, Sini Li and Yiting Sun and has published in prestigious journals such as BMC Medicine, Frontiers in Pharmacology and Journal of Thoracic Oncology.

In The Last Decade

Xinyang Du

11 papers receiving 326 citations

Peers

Xinyang Du

ONCOL

PRM

PHARM

Yisun Jeong South Korea

Wei-Ru Xu China

Yide Hu China

Man He China

Xiaoping Chen China

Guangjie Sui China

Huanhu Zhang China

Juan Zou China

Chuanbing Shi China

Yisun Jeong South Korea

Xinyang Du

129 ×0.9

ONCOL

40 ×0.4

PRM

179 ×1.9

86 ×1.0

PHARM

65 ×1.5

Citations per year, relative to Xinyang Du Xinyang Du (= 1×) peers Yisun Jeong

Countries citing papers authored by Xinyang Du

Since Specialization

Citations

This map shows the geographic impact of Xinyang Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xinyang Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xinyang Du more than expected).

Fields of papers citing papers by Xinyang Du

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xinyang Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xinyang Du. The network helps show where Xinyang Du may publish in the future.

Co-authorship network of co-authors of Xinyang Du

This figure shows the co-authorship network connecting the top 25 collaborators of Xinyang Du. A scholar is included among the top collaborators of Xinyang Du based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xinyang Du. Xinyang Du is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Sun, Yiting, Lei Xu, Chaoqiang Deng, et al.. (2025). Distinct survival, optimal combination strategy of immunotherapy, and immunophenotype in uncommon and 20ins EGFR-mut lung adenocarcinoma: a multi-center study. Molecular Biomedicine. 6(1). 88–88.

Li, Mengmeng, et al.. (2025). Exploring practical experience with different treatments in NSCLC patients with MET-deregulated: a retrospective analysis from the real world. BMC Pulmonary Medicine. 25(1). 35–35. 1 indexed citations

Zhang, Xiaojuan, Mina Zhang, Xinyang Du, et al.. (2024). Clinical efficacy and safety analysis of aumolertinib in real-world treatment of EGFR-mutated advanced non-small-cell lung cancer. Frontiers in Pharmacology. 15. 1331138–1331138. 5 indexed citations

Li, Mengmeng, et al.. (2023). The Prognostic Value of Programmed Death Ligand-1 in Advanced Non-Small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of Biomedical Research & Environmental Sciences. 4(12). 1728–1737. 1 indexed citations

Du, Xinyang, Hua Bai, Zhijie Wang, et al.. (2022). Establishment of prognostic nomograms for predicting the progression free survival of EGFR‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs. Thoracic Cancer. 13(9). 1289–1298. 4 indexed citations

Li, Weihua, Hua Bai, Jianchun Duan, et al.. (2022). Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non–small cell lung cancer. Thoracic Cancer. 13(21). 2951–2959. 6 indexed citations

Liu, Lihui, Hua Bai, Chao Wang, et al.. (2021). Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis. Journal of Thoracic Oncology. 16(7). 1099–1117. 92 indexed citations

Sun, Yiting, Jianchun Duan, Wenfeng Fang, et al.. (2021). Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC. BMC Medicine. 19(1). 239–239. 19 indexed citations

Wang, Ye, Yanfang Liu, Xinyang Du, Hong Ma, & Jing Yao. (2020). <p>The Anti-Cancer Mechanisms of Berberine: A Review</p>. Cancer Management and Research. Volume 12. 695–702. 153 indexed citations

10.

Wang, Zhijie, Jianming Ying, Jiachen Xu, et al.. (2020). Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non–Small Cell Lung Cancer. JAMA Network Open. 3(10). e2013770–e2013770. 32 indexed citations

11.

Liu, Yanfang, Lina Liu, Ye Wang, et al.. (2020). Clinical course and characteristics of patients with coronavirus disease 2019 in Wuhan, China: a single-centered, retrospective, observational study. Aging. 12(16). 15946–15953. 3 indexed citations

12.

Liu, Yanfang, Hong Ma, Ye Wang, Xinyang Du, & Jing Yao. (2019). <p>Cystatin SN Affects Cell Proliferation by Regulating the ERα/PI3K/AKT/ERα Loopback Pathway in Breast Cancer</p>. OncoTargets and Therapy. Volume 12. 11359–11369. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact